Abstract
Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Current Pharmaceutical Design
Title:Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases
Volume: 24 Issue: 26
Author(s): Anna Aiello*, Giuseppina Candore*, Giulia Accardi, Calogero Caruso, Claudia Colomba, Giovanni Duro, Caterina Maria Gambino, Mattia Emanuela Ligotti and Danilo Di Bona
Affiliation:
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
- University of Palermo, Department of Pathobiology and Medical Biotechnologies, Section of General Pathology, Corso Tukory 211, 90134, Palermo,Italy
Keywords: Autoimmune diseases, HLA ligands, immunogenetics, KIRs, translational medicine, viral infections.
Abstract: Killer immunoglobulin-like receptors (KIRs) regulate the activation of natural killer cells through their interaction with human leucocyte antigens (HLA). KIRs and HLA loci are highly polymorphic, and some of their combinations have been found to protect against viral infections or to predispose to autoimmune disorders. In particular, some activating KIRs profiles may be detrimental in autoimmune pathogenesis, and specific KIRs may be particularly aggressive in the clearance of different microorganisms, protecting individuals in the control of a given pathogen. So, considering that in the pathogenesis of many autoimmune disorders and infections innate immunity plays a key role, the recent development for KIRs characterization, diseases monitoring, and treatment becomes obvious. Here, we reviewed a growing body of evidence supporting the influence of KIRs variants and their interaction with ligands in the development of the main human autoimmune and viral diseases, highlighting the main applications in clinical practice.
Export Options
About this article
Cite this article as:
Aiello Anna *, Candore Giuseppina*, Accardi Giulia , Caruso Calogero , Colomba Claudia , Duro Giovanni , Gambino Maria Caterina , Ligotti Emanuela Mattia and Di Bona Danilo , Translation of Basic Research into Clinics: Killer Immunoglobulin-like Receptors Genes in Autoimmune and Infectious Diseases, Current Pharmaceutical Design 2018; 24 (26) . https://dx.doi.org/10.2174/1381612824666180911123249
DOI https://dx.doi.org/10.2174/1381612824666180911123249 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammation in Sepsis: Sepsis Associated Delirium
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model
Inflammation & Allergy - Drug Targets (Discontinued) COVID-19 in G6PD-deficient Patients, Oxidative Stress, and Neuropathology
Current Topics in Medicinal Chemistry Molecule of the Month
Current Topics in Medicinal Chemistry Management of Statin-Intolerant High-Risk Patients
Current Vascular Pharmacology Topical Formulations and Intradermal Injections of Tranexamic Acid in the Treatment of Hyperpigmentation - A Review
Letters in Drug Design & Discovery Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews A Merger of Rational Drug Design and Combinatorial Chemistry Development and Application of Peptide Secondary Structure Mimetics
Combinatorial Chemistry & High Throughput Screening Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) The Immunosuppressive Activity of Proinflammatory Cytokines in Experimental Models Potential for Therapeutic Intervention in Autoimmunity
Current Drug Targets - Inflammation & Allergy Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Biomolecules of Human Female Fertility - Potential Therapeutic Targets for Pharmaceutical Design
Current Pharmaceutical Design Rutin-Phospholipid Complex: An Innovative Technique in Novel Drug Delivery System- NDDS
Current Drug Delivery Status of Cytokines in Ischemia Reperfusion Induced Heart Injury
Cardiovascular & Hematological Disorders-Drug Targets Interaction of Chemokines with their Receptors - From Initial Chemokine Binding to Receptor Activating Steps
Current Medicinal Chemistry Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Abscopal Effect of Radiation Therapy and Signal Transduction
Current Signal Transduction Therapy